Lobbying Information
Subject Matters
- Aboriginal Affairs
- Budget
- Consumer Issues
- Health
- Industry
- Intellectual Property
- International Trade
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- The upcoming Food and Drugs Act Modernization legislative proposal (Act and Regulations) as it relates to improving the efficiency of the drug review and approval process.
Legislative Proposal, Bill or Resolution, Regulation
- Food and Drugs Act & Regulations with respect to Drug Export Restrictions and international trade.
- The Food and Drugs Act and Regulations with respect to their impact on addiction treatments.
Policies or Program
- A national pharmacare strategy with respect to the need for full coverage/reimbursement of opioid dependence treatments and addiction treatments.
- Common Drug Review with respect to reimbursement decisions and the approval process.
- Coverage of opioid dependence treatments and addiction treatments with respect to Canadian Forces returning to Canada from active duty overseas.
- Government of Canada Drug Plans, with respect to the reimbursement of therapeutic products relevant beneficiaries.
- Non-Insured Health Benefits under Health Canada with regards to reimbursement criteria of opioid dependence & addiction treatments for First Nations, Inuit and Metis in Canada.
- The National Anti-Drug Strategy with respect to public relations and awareness programs relating to addiction and opioid dependence.
- The federal Science & Technology Strategy and/or any federal Government policy or program initiatives to support Research and Development in Canada, and advocate for the development of a pharmaceutical sectoral strategy in support of more research & development in Canada
Regulation
- Patented Medicine Prices Review Board (PMPRB) Regulations as it relates to reporting requirements and pricing guidelines.
- Patented Medicines Regulations (Notice of Compliance) with respect to regulating intellectual property for therapeutic products
Communication Techniques
-
Written communication
-
Oral communication
-
Participation in Industry Associations and delegations
Government Institutions
-
Aboriginal Affairs and Northern Development Canada
-
Canadian Institutes of Health Research (CIHR)
-
Correctional Service of Canada (CSC)
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
House of Commons
-
Industry Canada
-
Justice Canada (JC)
-
National Defence (DND)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Safety Canada (PS)
-
Royal Canadian Mounted Police (RCMP)
-
Senate of Canada
-
Veterans Affairs Canada (VAC)
In-house Corporation Details
Description of activities
Reckitt Benckiser Pharmaceuticals Inc. is committed to optimizing standards of patient care and minimizing risks of diversion and abuse through programs of education and intervention that we believe represent a benchmark for the pharmaceutical industry in the therapeutic area of addiction treatment. Our Risk Management Program includes educational efforts that emphasize the safe and effective use of buprenorphine and are directed toward physicians, pharmacists, counselors, and patients and their families. All educational materials developed by Reckitt Benckiser Pharmaceuticals Inc. focus on reinforcing the matrix of care model to provide patients and their treatment providers with information that supports best medical practices. Our comprehensive educational endeavors are intended to educate healthcare providers and patients on the proper use as well as the risks associated with Suboxone and Subutex sublingual tablets.
Responsible officer name and position during the period of this registration
Gary Phillips,
President & CEO (North America)
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
10710 Midlothian Turnpike
Richmond, VA 23235
United States of America
Telephone number:
804-379-1090
Fax number:
804-379-1215
Parent Company Information
- Reckitt Benckiser Group / Groupe Reckitt Benckiser
-
Suite 103
105 Bath Road
Slough, Berkshire SL13UH
United Kingdom
Subsidiary Beneficiary Information
Reckitt Benckiser Pharmaceuticals Inc / Reckitt Benckiser Pharmaceuticals Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Tina Cantrill,
Business Unit Director (Canada) |
No public offices held
- Rolley Johnson,
Vice President, Treatment & Health Policy |
No public offices held
- Gary Phillips,
President & CEO (North America) |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties